AI Analysis | Feedback

Analogies for Arcturus Therapeutics (ARCT):

• A developing-stage Moderna.
• Like BioNTech, but also developing RNA therapies for rare diseases.

AI Analysis | Feedback

• LUNAR-OTC: A development program for treating ornithine transcarbamylase (OTC) deficiency, a rare liver disease.
• LUNAR-CF: A development program aimed at treating cystic fibrosis lung disease.
• LUNAR-COV19: A vaccine program for the prevention of COVID-19.
• LUNAR-FLU: A vaccine program under development for influenza.

AI Analysis | Feedback

Arcturus Therapeutics (ARCT) primarily generates revenue through collaborations and partnerships with other companies and institutions for the development and potential commercialization of its RNA medicines and vaccines. Its major customers are:

• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson, symbol: JNJ)
• Ultragenyx Pharmaceutical, Inc. (symbol: RARE)
• CureVac AG (symbol: CVAC)
• Millennium Pharmaceuticals, Inc. (a subsidiary of Takeda Pharmaceutical Company Limited, symbol: TAK)
• Vinbiocare Biotechnology Joint Stock Company
• Singapore Economic Development Board
• Duke-NUS Medical School

AI Analysis | Feedback

• Vinbiocare Biotechnology Joint Stock Company

AI Analysis | Feedback

Joseph E. Payne, President & Chief Executive Officer

Joseph E. Payne is the President and Chief Executive Officer of Arcturus Therapeutics, Inc., and has served on its Board since March 2013. He co-founded Arcturus Therapeutics in 2013. With over 20 years of drug discovery experience, his background includes roles at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto. He has been involved in ushering novel therapeutics to the clinic, including targeted RNA medicines utilizing lipid-mediated delivery technologies, and has over 40 publications and patents, and several investigational new drug (IND) clinical candidates to his name.

Andrew Sassine, Chief Financial Officer

Andrew Sassine was appointed Chief Financial Officer of Arcturus Therapeutics, effective January 1, 2019, after serving as Interim Chief Financial Officer since August 2018 and as a board member since May 2018. He previously held various positions at Fidelity Investments from 1999 to 2012, most recently as a portfolio manager. During his time at Fidelity, from 2004 to 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund, and the Fidelity Advisor International Small Cap Opportunities Fund. Prior to joining Fidelity, he was a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine serves or has served on the boards of Nasdaq-listed ICAD Inc., Gemphire Therapeutics, Inc. (GEMP), and privately held ComHear Inc.. He also previously served on the boards of Acorn Energy, Inc., CNS Response, Inc., and FluoroPharma Medical, Inc..

Dr. Padmanabh Chivukula, Chief Scientific Officer and Chief Operating Officer

Dr. Padmanabh Chivukula is the co-founder of Arcturus Therapeutics and has served as the Chief Scientific Officer and Chief Operating Officer since 2013. He possesses a deep foundation in nanoparticle technology and has been instrumental in building and advancing the company's research competencies and pipeline in RNA therapeutics and vaccines. Before co-founding Arcturus, Dr. Chivukula held key roles at Nitto, including Group Leader and Chief Scientist, where he led the polymeric RNAi research department. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Utah, specializing in nanoparticle technology.

Lance Kurata, Chief Legal Officer

Lance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to joining Arcturus, he was a partner at Mintz Levin from 2006 to 2020, where he chaired the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson and led their nationwide technology transactions practice. Earlier in his career, from 1996 to 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, focusing on strategic collaborations, public and private financings, mergers and acquisitions, and corporate governance.

Ye Zhang, Chief Regulatory Officer

Ye Zhang is the Chief Regulatory Officer for Arcturus Therapeutics, responsible for establishing the Regulatory Affairs department and overseeing regulatory strategy, regulatory CMC, regulatory operations, and labeling for vaccines and rare disease therapeutics. Under her leadership, her team successfully supported the COVID-19 Vaccine NDA filing with the PMDA, leading to Arcturus's first drug product approval and the world's first self-amplifying mRNA vaccine approval. Dr. Zhang brings over 20 years of experience in regulatory and drug development for vaccines, biologics, and small molecules.

AI Analysis | Feedback

The key risks to Arcturus Therapeutics' business are primarily centered on clinical development and regulatory hurdles, the protection of its core intellectual property, and ongoing financial sustainability challenges.

1. Clinical Trial Outcomes and Regulatory Approval: As an RNA medicines company, Arcturus Therapeutics' success is highly dependent on the successful advancement of its drug candidates through clinical trials and obtaining regulatory approvals. Recent interim Phase 2 data for its cystic fibrosis (CF) program, ARCT-032, "fell short of expectations," showing no meaningful improvement in lung function (FEV1), which led to a significant stock price decline and analyst downgrades. While the ARCT-032 program is proceeding into a 12-week Phase 2 study, the initial results have cast doubt on its potential in late-stage development. Similarly, ARCT-810 for ornithine transcarbamylase (OTC) deficiency, another key pipeline asset, faces challenges related to durability, a competitive landscape, and high commercial hurdles, despite showing early biomarker improvement. The company has strategically pivoted to focus predominantly on these two rare disease therapeutic programs, making their clinical and regulatory success critical for the company's future.
2. Intellectual Property and Trade Secret Misappropriation: Arcturus Therapeutics faces significant risks related to protecting its proprietary lipid nanoparticle (LNP) delivery technology, a core component of its mRNA platform. The company has filed a lawsuit against AbbVie and Capstan Therapeutics, alleging misappropriation of its LNP delivery know-how, reportedly after former Arcturus personnel joined Capstan and transferred proprietary information. This type of intellectual property dispute can disrupt ongoing clinical trial timelines, delay regulatory submissions, and complicate the overall regulatory strategy, potentially impacting not just a single program but the entire pipeline due to the platform nature of the technology. There is also a historical precedent of litigation involving a former CEO regarding alleged attempts to transfer the company's intellectual property.
3. Financial Performance and Profitability: Arcturus Therapeutics continues to face challenges in achieving profitability. The company reported a substantial net loss of $65.8 million for fiscal year 2025 and is not projected to become profitable within the next three years. Analysts anticipate a decline in sales in the current year, and while the company has extended its cash runway into the second quarter of 2028 through strategic resource reallocation, the underlying profitability concerns persist. The high cash burn rate and history of losses indicate a risk of future dilution if additional funding becomes necessary to sustain its costly drug development programs. Furthermore, the company's Altman Z-Score of 0.89 places it in a "distress zone," suggesting a potential risk of bankruptcy within the next two years.

AI Analysis | Feedback

AI Analysis | Feedback

Addressable Markets for Arcturus Therapeutics' Main Products and Services

Arcturus Therapeutics Holdings Inc. (ARCT) is an RNA medicines company developing vaccines and therapeutics for infectious, liver, and respiratory rare diseases. The addressable markets for its main product candidates are substantial across various indications:

• Ornithine Transcarbamylase (OTC) Deficiency (LUNAR-OTC program): The global market for Ornithine Transcarbamylase (OTC) Deficiency treatment was valued at approximately USD 1.2 billion in 2023 and is projected to reach USD 2.3 billion by 2032. Another estimate places the global market at USD 1,284 million in 2025, expected to expand to USD 2,341.6 million by 2033. The North American market alone held a significant share, estimated at USD 475.08 million in 2025.
• Cystic Fibrosis (LUNAR-CF program): The global cystic fibrosis therapeutics market was calculated at USD 13.88 billion in 2025 and is projected to reach around USD 35.68 billion by 2035. Another report estimates the global market at USD 13.49 billion in 2026, with a projection to reach approximately USD 44.72 billion by 2035. The market in the United States alone was approximately USD 9,473 million in 2023.
• COVID-19 Vaccines (LUNAR-COV19 program): The global COVID-19 vaccine market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033. Another analysis indicates the global COVID-19 vaccine market size was USD 13.71 billion in 2025 and is projected to contract to USD 8.28 billion by 2030, reflecting a shift from mass immunization.
• Influenza Vaccines (LUNAR-FLU program): The global influenza vaccine market was estimated at USD 7.91 billion in 2023 and is projected to reach USD 12.58 billion by 2030. Other estimates for the global market include USD 7.2 billion in 2024, reaching USD 12.8 billion by 2033, and USD 9.2 billion in 2025, projected to grow to USD 22.49 billion by 2034. North America was the largest revenue-generating market for influenza vaccines in 2023 and accounted for USD 4.95 billion in 2025.
• Hepatitis B Virus Treatment: The global hepatitis B therapeutics market size was USD 2.48 billion in 2025 and is projected to grow to USD 6.66 billion by 2034. Another report estimates the global Hepatitis B Treatment market size at USD 4.52 billion in 2025, projected to reach USD 7.74 billion by 2033. North America dominated the market with a 52.31% share in 2025, with the U.S. market specifically projected to grow from USD 1.00 billion in 2025 to USD 1.54 billion by 2033.
• Non-alcoholic Steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH): The global Non-Alcoholic Steatohepatitis Treatment Market was valued at USD 7.70 billion in 2024 and is projected to reach USD 55.52 billion by 2032. Similarly, the global NASH/MASH Treatment Market reached US$ 7.87 billion in 2024 and is expected to reach US$ 31.76 billion by 2033. The U.S. NASH treatment market accounted for approximately 76% of the regional share in 2024, valued at $4.56 billion, and is forecast to rise to $32.55 billion by 2032.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Arcturus Therapeutics (ARCT) Over the Next 2-3 Years:

1. Commercialization of KOSTAIVE® (LUNAR-COV19) and other COVID-19 vaccine sales/royalties: Arcturus developed KOSTAIVE®, the world's first approved self-amplifying mRNA COVID vaccine. While revenue from the CSL collaboration has seen reductions as the program transitioned from development to the commercial phase, there is ongoing potential for revenue through sales, supply agreements, and royalties as it gains further regulatory approvals globally. For example, a UK Marketing Authorization Application (MAA) filing for KOSTAIVE is anticipated in Q2 2025, followed by a U.S. Biologics License Application (BLA) filing expected in Q3 2025. The company also has existing supply agreements with entities like the Israeli Ministry of Health and Singapore's Economic Development Board.
2. Advancement and potential commercialization of LUNAR-CF (ARCT-032) for Cystic Fibrosis: ARCT-032 is an inhaled mRNA therapeutic candidate for cystic fibrosis. Positive interim data from Phase 1b and Phase 2 studies have shown improvements in lung function (FEV1) and reduction in mucus plugs in certain cystic fibrosis patients. Arcturus plans to initiate a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026, targeting those with Class I mutations. This program remains a key strategic focus for the company.
3. Advancement and potential commercialization of LUNAR-OTC (ARCT-810) for Ornithine Transcarbamylase (OTC) Deficiency: ARCT-810 is an intravenously administered investigational mRNA therapeutic designed to express the normal functional OTC enzyme in the liver. Positive interim Phase 2 data have indicated significant improvements in urea cycle function and glutamine levels, along with a favorable safety profile. Arcturus aims to achieve alignment with regulatory agencies regarding pivotal studies for ARCT-810 in adults and young children with OTC deficiency, positioning it as a significant pipeline asset.
4. Revenue from existing and future collaboration partnerships: Arcturus generates revenue through various strategic alliances and collaborations, including license fees, consulting and technology transfer fees, reservation fees, and collaborative payments from research and development arrangements with pharmaceutical and biotechnology partners. While some collaboration revenue may fluctuate as programs mature, ongoing partnerships, such as the global collaboration with CSL Seqirus for innovative mRNA vaccines and a joint venture in Japan (ARCALIS) for mRNA vaccine and therapeutic manufacturing, continue to present opportunities for milestone payments and royalties.
5. Progress of the LUNAR-FLU vaccine program: Arcturus has a partnered mRNA vaccine program for influenza. Further advancement and potential commercialization of this program, especially through its collaboration with partners like CSL Seqirus, could contribute to future revenue growth.

AI Analysis | Feedback

Share Repurchases

Arcturus Therapeutics has not reported any share repurchase programs or made significant share repurchases in the last 3-5 years.

Share Issuance

• The number of common shares outstanding for Arcturus Therapeutics increased from 27,000 thousand at December 31, 2024, to 28,414 thousand at December 31, 2025.
• As of March 4, 2025, there were 26,915,243 shares of common stock outstanding.

Inbound Investments

• In December 2022, Arcturus Therapeutics received a $200 million upfront payment as part of an exclusive global collaboration and license agreement with CSL Seqirus for mRNA vaccines.
• By March 2023, the company achieved an additional $90 million in development milestones under the CSL collaboration.
• As of December 31, 2024, Arcturus had achieved approximately $473.1 million in total upfront payments and milestones from the CSL collaboration.
• In May 2025, Arcturus Therapeutics also received an initial European Union (EU) approval milestone payment from its partnership with CSL.

Outbound Investments

• In February 2021, Arcturus Therapeutics acquired an exclusive license from Alexion Pharmaceuticals for patent-pending inventions related to nucleic acid purification technologies to enhance large-scale and faster mRNA production.

Capital Expenditures

• In the last 12 months prior to the data presented in a March 2026 report, Arcturus Therapeutics reported minimal capital expenditures of approximately -$230,000.
• Research and development expenses for the fourth quarter of 2025 included higher facilities and equipment costs due to lease impairment.
• Facility-related expenses are typically included within the company's research and development expenditures.